gw420867x has been researched along with uc-781 in 2 studies
Studies (gw420867x) | Trials (gw420867x) | Recent Studies (post-2010) (gw420867x) | Studies (uc-781) | Trials (uc-781) | Recent Studies (post-2010) (uc-781) |
---|---|---|---|---|---|
17 | 5 | 2 | 70 | 6 | 21 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Jorgensen, WL; Kroeger Smith, MB; Rizzo, RC; Smith, RH; Tirado-Rives, J; Udier-Blagović, M; Wang, DP; Watkins, EK | 1 |
Balzarini, J; Burt, V; Carbonez, A; De Clercq, E; Kleim, JP | 1 |
2 other study(ies) available for gw420867x and uc-781
Article | Year |
---|---|
Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations.
Topics: Alkynes; Anilides; Benzoxazines; Computer Simulation; Cyclopropanes; HIV Reverse Transcriptase; Hydrogen Bonding; Models, Molecular; Monte Carlo Method; Nevirapine; Oxazines; Protein Binding; Quinoxalines; Regression Analysis; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Uracil | 2002 |
Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Anilides; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Delavirdine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Microbial; Furans; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Mutation; Nevirapine; Oxazines; Quinoxalines; Reverse Transcriptase Inhibitors; Thioamides; Uracil | 2000 |